Molecule

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Leading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine Innovation

Retrieved on: 
Thursday, March 14, 2024
Molecule, Learning Technology Partners, Personalized medicine, Organization, Conference, Innovation, Biotechnology, AstraZeneca, Partnering, Convention, Virtual humans, Data science, Drug discovery, RWE, Bias, Shape, Social media, Stargate Atlantis, RWD, Transformation, Bristol Myers Squibb, Digital twin, Student, LDN, Investment, Vacuum, RDN, Water, Machine learning, MD Anderson Cancer Center, Pharmaceutical industry

BOSTON, March 14, 2024 /PRNewswire/ -- Life science innovation doesn't happen in a vacuum. It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.

Key Points: 
  • It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.
  • From April 15-17, more than 3,000 pharmaceutical, biotechnology and IT leaders will gather for the 23rd annual Bio-IT World Conference & Expo in Boston to put this model into action.
  • "Precision medicine is at a tipping point as both scientific and computing capabilities explode," said Cindy Crowninshield, RDN, LDN, Executive Event Director.
  • This year, the Bio-IT World conference will focus on how to keep the creative pipeline flowing by bringing rising scientists into the fold.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Friday, March 8, 2024
Molecule, Therapy, IPF, SAN, Research, Investment, Obesity, Apelin, Idiopathic pulmonary fibrosis, Growth, GIPR, GIP, A1C, Interim, Safety, GPCR, G&A, Glycated hemoglobin, Pharmaceutical industry

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Retrieved on: 
Wednesday, March 6, 2024
Molecule, TREM2, Vigil, Pharmacology, Doctor of Philosophy, Microglia, Conference, Drug

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.

Key Points: 
  • WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.
  • The presentation outlines preclinical data on the agonist pharmacology of VG-3927, its effect on AD-associated neuropathological endpoints, and its potential as a disease-modifying therapeutic for the treatment of AD.
  • “As the first and only small molecule TREM2 agonist to enter clinical development, we are thrilled to have an opportunity to further demonstrate the differentiated profile for VG-3927 and how it could represent a significant treatment advancement for those living with AD,” said David Gray, PhD, Chief Science Officer at Vigil.
  • “Having recently commenced dosing in our Phase 1 healthy volunteer clinical trial evaluating VG-3927, we look forward to further investigating this mechanism of action and its potential as a disease-modifying therapeutic.”
    Title: Characterization of the First Small Molecule TREM2 Agonist, VG-3927, for Clinical Development in Alzheimer’s Disease

Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024

Retrieved on: 
Tuesday, March 5, 2024
Molecule, Clinical research, AACR, Molecular biology, Real Salt Lake, Gene expression, Abstract, Plasma, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced three abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5 – 10 in San Diego, California.

Key Points: 
  • BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced three abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5 – 10 in San Diego, California.
  • The scientific data to be presented at AACR 2024 add to the growing body of evidence supporting Precede Biosciences’ unique ability to inform on the activation status of druggable targets, pathways, and resistance mechanisms all from 1mL of plasma.
  • Details on the presentations are as follows:
    Title: Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer
    Session: Experimental and Molecular Therapeutics, Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes, Poster Section 26
    Session: Clinical Research, Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression, Poster Section 43
    Follow Precede Biosciences on X/Twitter and LinkedIn for the latest company updates from #AACR24.

Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease

Retrieved on: 
Tuesday, February 27, 2024
Molecule, Glucocerebrosidase, DSM-IV codes, Neuroprotection, Doctor of Philosophy, Conference

CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.

Key Points: 
  • CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
  • “We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio.
  • “We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase.
  • Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.”
    Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024
Molecule, SAN, MSA, Treatment, Conceptual model, Iron, Multiple system atrophy, Annual general meeting, AAN, ASX, ATH, Therapy, Disease, Vanderbilt University, American Academy, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.
  • “We are thrilled to be presenting at this prestigious international neurology conference, including new baseline biomarker data on ATH434 from our ongoing Phase 2 randomized, double blind clinical trial in multiple system atrophy (MSA), as well as compelling preclinical primate data on ATH434 in Parkinson’s disease,” said, David Stamler, M.D., Chief Executive Officer of Alterity.
  • “In addition, we remain in the vanguard of biomarker evaluation of MSA, as our partners at Vanderbilt University will present important data from our bioMUSE natural history study.
  • AAN promises to be a very productive conference for us as we advance our MSA program toward data later this year and expand our development toward Parkinson’s disease.”
    A Phase 2 Study of ATH434, a Novel Inhibitor of α-Synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA)
    Effects of ATH434, a Clinical-phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Thursday, March 7, 2024
Research, Technology, Other Health, Biotechnology, Hardware, Pharmaceutical, Health, Science, Oncology, Other Science, Molecule, Breakfast, PTM, Booth, Protein sequencing, Conference, Doctor of Philosophy, Protein, Johns Hopkins University, Mass spectrometry, Proteomics, Proteome, Assistant professor, Body modification, Hyatt Regency Portland, Microscope

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Molecule, OTCQB, Regeneration, MSCL, TSX, Animal, DMD, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, Skeletal muscle, Conference, Event, FSHD, Poster, Trauma, Myopathy, Episcopal conference, Face

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

Key Points: 
  • Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.
  • In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
  • We believe the muscle injury data further expand and broaden the potential for SAT-3247 into non-dystrophy disease indications as well as multiple forms of muscle injury or trauma in otherwise healthy individuals.
  • We continue on our development plan to advance SAT-3247 into first-in-human clinical trials mid-year.”
    These data are being presented in a poster at the 2024 MDA Clinical & Scientific Conference being held March 3-6 in Orlando.

Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer

Retrieved on: 
Monday, February 26, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Data science, Molecule, B cell, Research fellow, Strategic management, MBA, Business development, Vaccine, IPO, University, Therapy, Business, Vassar College, Venture round, Financial management, Jefferies, Partnership, Management

Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Anthony Baldor has been appointed Chief Financial Officer.

Key Points: 
  • Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Anthony Baldor has been appointed Chief Financial Officer.
  • Mr. Baldor brings 20 years of financial management experience in the biotech industry including fundraising, business development, and corporate strategy.
  • Mr. Baldor comes to Diakonos from 4D Molecular Therapeutics where he played critical leadership roles in the Series C, IPO and partnership activities as Vice President of Corporate Strategy and Development.
  • “Anthony Baldor is a critical and timely addition to the Diakonos management team,” said Diakonos Chief Executive Officer Mike Wicks.